Spark Therapeutics raises $94M; Upstart Evelo opens HQ;

@FierceBiotech: Biotech bad boy Martin Shkreli faces a new set of angry foes: federal prosecutors. News | Follow @FierceBiotech

@JohnCFierce: Gilead steps in to replace AbbVie with $2B Galapagos collaboration. News | Follow @JohnCFierce

@DamianFierce: it is with solemn humility that I now accept the mantle of Biotech's Bad Boy. thank you. | Follow @DamianFierce

> Gene therapy player Spark Therapeutics raised $94 million in a follow-on offering. Release

> Cambridge, MA-based Evelo Therapeutics has cut the ribbon on its new 9,000-square-foot HQ. The Flagship portfolio company--focused on the microbiome--was launched a few weeks ago with a $35 million round. Release

Medical Device News

@FierceMedDev: NYU researchers roll out ResearchKit app as part of concussion-monitoring study. Article | Follow @FierceMedDev

@EmilyWFierce: In this week's Dx Digest, $ILMN makes waves in China and $LH buys a women's health lab. More | Follow @EmilyWFierce

> VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report

> Australian teams aims to create dialysis-like blood filtration system to treat cancer. Article

> Startup touts first-in-man study of its sensor for cardiac ablation catheters in hopes of partnership. Story

Pharma News

@FiercePharma: Toxin from sea algae impacts memory, behavior in California sea lions: Study. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Mylan wants some payback for plants it bought from Strides that have been cited by FDA. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca shrugs off pharma's emerging markets slowdown, but Lilly's suffering. Article | Follow @CarlyHFierce

> GSK's Avandia is free and clear at the FDA, 8 years after heart-safety controversy began. Story

> Top-earning directors on the S&P 500? Regeneron and Endo, at $1.4M and up. Report

> FBI arrests controversial Turing CEO Martin Shkreli on securities fraud charges. Article

CRO News

> PPD reportedly on the block for $8B. Report

> Recipharm signs on to manufacture an in-development cancer drug, investing in a Swedish biotech. Article

> On the rebound, AMRI trades $52M for a testing firm. News

Pharma Manufacturing News

> AstraZeneca shifts supply chain strategy from air to sea freight shipments. Report

> GSK opens Australia pilot plant to test blow-fill-seal technology on vaccines. Article

> WuXi and PRA canceling joint venture in China. Item

> Deadline looms to meet new label and insert requirements in Taiwan. More

> WuXi to sell AstraZeneca China's largest biologics plant for $100M. News

Pharma Asia News

> Indian healthcare IPOs raise $300M. Item

> Don't count India out yet in biosimilars race, Quintiles exec says. More

> YiChang IPO joins other drug companies in tough IPO market. Report

> Taiwan sets June 2016 deadline on new packaging, insert rules. Story

> WuXi venture unit raises $290M for 'find in U.S., build in China' venture fund. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.